business news

MilliporeSigma invests $131M in Molsheim for life-saving therapies

MilliporeSigma invests $131M in Molsheim for life-saving therapies

MilliporeSigma, the US and Canadian Life Sciences arm of German pharma Merck KGaA, has reportedly invested €130 million ($131 million) in the city of Molsheim, France in order to bolster the manufacturing capabilities of single-use assemblies, one of the key technology utilized for producing COVID-19 vaccines as well as numerous other life-saving therapies.

As per reports, this marks the biggest investment ever made in the 50-year history of the city and will create over 800 jobs by 2028.

Belén Garijo, CEO of Merck KGaA, stated that the group is determined in delivering patients across Europe as well as globally with reliable access to life-saving therapies and vaccines.

He added that this investment in France will act as an integral part of the group’s plan to expand the global manufacturing footprint and providing exceptional customer value worldwide.

As per the plan, an administrative building, a new logistics warehouse, and 37,000-sq-ft ISO7 clean rooms will be functional by the end of 2024.The production is expected to increase gradually to full capacity by 2028.

Last year, the group’s Life Science affiliate added a single-use assembly production unit worth €25 million ($25 million).

The investment will also make Molsheim the first location in Europe where MilliporeSigma manufactures product, along with its other productions based in the US, Danvers, Massachusetts, and China, in Wuxi.

Matthias Heinzel, Board Member, Merck KGaA, stated that France is integral to the group’s strategy in driving long-term growth and extending its global leadership position in the Life Science industry.

Heinzel added that in recent years, several biopharmaceutical manufacturers have been using single-use technologies due to their speed, flexibility, lower contamination risk, and cost-saving features, leading to double-digit growth in this market segment.

He further conveyed that this trend was further reinforced by the Covid-19, adding that the investment will quicken the delivery of crucial products and technologies needed by the group’s customers for bringing breakthrough treatments from across the world.

Source credit:

About the author

Meghna Singh

An English Literature graduate, Meghna Singh ventured into the profession of content development to incorporate her knack for writing articles across verticals including technology, healthcare, business, and alike for News Origins and Newsorigins. She has also completed her MBA in Tourism and worked as a content creator in the field of product development.